ClinicalTrials.gg
CompletedNCT00830167Updated Jan 25, 2021Results posted

Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia

A Phase 3 interventional study of Placebo and Pregabalin in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 37 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.

Enrollment
7th of 30
498 · median 199
Started
2009
with 2 others
Phase 3
13 of 30
none open now
Registered
9th of 30
by date
Lead sponsor
15 of 30
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 7th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 9th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pregabalin in Fibromyalgia, or all of them as a file.
02

Study summary

This study, will compare pregabalin with placebo for the duration of 15 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACR criteria for fibromyalgia
  • A score of more or equal to 40 mm on the Pain VAS
  • An average score more or equal to 4 on 4 daily pain diaries

Exclusion criteria

Exclusion Criteria:

  • Patients with other severe pain conditions
  • Patients with severe depression
  • Patients taking excluded medications
  • Patients with suicidality
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
498 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Pregabalin

    Drug: Pregabalin

Interventions

  • DrugPlacebo

    Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)

  • Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)

06

What researchers measure

Primary outcomes

  1. Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline

    Change from baseline in mean NRS-Pain scores at endpoint-LOCF. Daily pain scores were assessed on an 11-point numerical rating scale \<(NRS)-Pain\> ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline, Week 15 or study discontinuation

Secondary outcomes

  1. Percentage of Participants Who Was Categorized as "Improved (Very Much Improved, Much Improved, or a Minimally Improved)" According to the Patient Global Impressions of Change (PGIC)

    PGIC was defined as participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Change was defined as a score of 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse) , 6 (much worse) or 7 (very much worse) on the scale.

    Time frame: Week 15 or study discontinuation

  2. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Disturbance

    MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep disturbance. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  3. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Snoring

    MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of snoring. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  4. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Awaken Short of Breath or With a Headache

    MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of the symptom. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  5. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Quantity of Sleep

    MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score indicates greater quantity of sleep. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  6. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Adequacy

    MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep adequacy. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  7. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Somnolence

    MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of somnolence. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  8. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Overall Sleep Problems Index

    MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of overall sleep problems. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  9. Medical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint

    MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Optimal sleep was defined as sleep quantity of 7 or 8 hours per night.

    Time frame: Week 15 or study discontinuation

  10. Change From Baseline in Sleep Quality Score at Endpoint

    Change: Mean sleep quality score at endpoint minus mean at baseline. Sleep quality scores range from 0-10 with higher scores indicating decreased sleep quality.

    Time frame: Baseline, Week 15 or study discontinuation

  11. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Total Scores

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  12. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Physical Function

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  13. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Feel Good

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  14. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Work Miss

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  15. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Housework

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  16. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Pain

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  17. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Tiredness

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  18. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Morning

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  19. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Stiffness

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  20. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Anxious

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  21. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Depression

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  22. Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Physical Functioning

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  23. Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Physical

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  24. Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Bodily Pain

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  25. Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- General Health Perception

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  26. Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Social Functioning

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  27. Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Emotional

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  28. Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Vitality

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  29. Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Mental Health

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

  30. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety

    Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.

    Time frame: Baseline, Week 15 or study discontinuation

  31. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression

    Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.

    Time frame: Baseline, Week 15 or study discontinuation

  32. Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint

    The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 15 or study discontinuation

07

Results

Posted Jun 1, 2012

Participant flow

Participant flow — Overall Study
MilestonePlaceboPregabalin
Started248250
Completed208207
Not completed4043
Withdrew: Lack of efficacy2610
Withdrew: Adverse event824
Withdrew: Not meeting entrance criteria25
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up01
Withdrew: Protocol violation01
Withdrew: Other22

Outcome measures

PrimaryChange From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline

Change from baseline in mean NRS-Pain scores at endpoint-LOCF. Daily pain scores were assessed on an 11-point numerical rating scale \<(NRS)-Pain\> ranging from 0 (no pain) to 10 (worst possible pain).

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline
Scores on a scalePlaceboPregabalin
Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline-1.03 ± 0.12-1.48 ± 0.12
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0046 (The analysis was conducted using 1-sided test with the significance level of 0.025. Actual significance level was calculated based on O'Brien-Fleming type alpha spending function of Lan and DeMets (1983).) · Mean difference (final values): -0.44 · 95% CI -0.78 to -0.11
SecondaryPercentage of Participants Who Was Categorized as "Improved (Very Much Improved, Much Improved, or a Minimally Improved)" According to the Patient Global Impressions of Change (PGIC)

PGIC was defined as participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Change was defined as a score of 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse) , 6 (much worse) or 7 (very much worse) on the scale.

Time frame:
Week 15 or study discontinuation
Reported as:
Number · Percentage of participants
Percentage of Participants Who Was Categorized as "Improved (Very Much Improved, Much Improved, or a Minimally Improved)" According to the Patient Global Impressions of Change (PGIC)
Percentage of participantsPlaceboPregabalin
Percentage of Participants Who Was Categorized as "Improved (Very Much Improved, Much Improved, or a Minimally Improved)" According to the Patient Global Impressions of Change (PGIC)62.170.0
Statistical analysis
  • Placebo vs Pregabalin · Chi-squared · p = 0.0078 (The analysis was conducted using 2-sided test with the significance level of 0.05.)
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Disturbance

MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep disturbance. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Disturbance
Scores on a scalePlaceboPregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Disturbance-8.13 ± 1.31-17.62 ± 1.31
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = <0.0001 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -9.48 · 95% CI -13.12 to -5.85
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Snoring

MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of snoring. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Snoring
Scores on a scalePlaceboPregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Snoring-1.61 ± 1.333.37 ± 1.33
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.9958 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 4.98 · 95% CI 1.29 to 8.68
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Awaken Short of Breath or With a Headache

MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of the symptom. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Awaken Short of Breath or With a Headache
Scores on a scalePlaceboPregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Awaken Short of Breath or With a Headache-3.02 ± 1.36-8.01 ± 1.36
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0049 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -4.99 · 95% CI -8.77 to -1.21
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Quantity of Sleep

MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score indicates greater quantity of sleep. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Quantity of Sleep
Scores on a scalePlaceboPregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Quantity of Sleep0.17 ± 0.060.46 ± 0.06
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0007 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 0.29 · 95% CI 0.11 to 0.47
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Adequacy

MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep adequacy. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Adequacy
Scores on a scalePlaceboPregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Adequacy8.02 ± 1.4115.50 ± 1.40
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = <0.0001 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 7.48 · 95% CI 3.58 to 11.38
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Somnolence

MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of somnolence. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Somnolence
Scores on a scalePlaceboPregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Somnolence-4.66 ± 1.296.65 ± 1.28
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 1.0000 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 11.31 · 95% CI 7.74 to 14.87
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Overall Sleep Problems Index

MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of overall sleep problems. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Overall Sleep Problems Index
Scores on a scalePlaceboPregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Overall Sleep Problems Index-7.07 ± 0.96-10.06 ± 0.95
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0137 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -2.99 · 95% CI -5.65 to -0.33
SecondaryMedical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint

MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Optimal sleep was defined as sleep quantity of 7 or 8 hours per night.

Time frame:
Week 15 or study discontinuation
Reported as:
Number · Participants
Medical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint
ParticipantsPlaceboPregabalin
Medical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint5371
Statistical analysis
  • Placebo vs Pregabalin · Regression, Logistic · p = 0.0687 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Odds ratio (or): 1.45 · 95% CI 0.90 to 2.35
SecondaryChange From Baseline in Sleep Quality Score at Endpoint

Change: Mean sleep quality score at endpoint minus mean at baseline. Sleep quality scores range from 0-10 with higher scores indicating decreased sleep quality.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Sleep Quality Score at Endpoint
Scores on a scalePlaceboPregabalin
Change From Baseline in Sleep Quality Score at Endpoint-0.79 ± 0.12-1.52 ± 0.12
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = <0.0001 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.73 · 95% CI -1.06 to -0.40
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Total Scores

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Total Scores
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Total Scores-7.26 ± 1.08-10.59 ± 1.07
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0144 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -3.33 · 95% CI -6.31 to -0.35
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Physical Function

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Physical Function
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Physical Function-0.19 ± 0.11-0.47 ± 0.11
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0376 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.28 · 95% CI -0.59 to 0.03
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Feel Good

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Feel Good
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Feel Good-0.82 ± 0.17-1.45 ± 0.17
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0052 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.63 · 95% CI -1.12 to -0.15
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Work Miss

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Work Miss
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Work Miss-0.30 ± 0.15-0.31 ± 0.15
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.4768 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.01 · 95% CI -0.42 to 0.40
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Housework

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Housework
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Housework-1.00 ± 0.15-1.32 ± 0.15
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0729 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.31 · 95% CI -0.74 to 0.11
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Pain

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Pain
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Pain-1.06 ± 0.15-1.46 ± 0.15
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0238 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.41 · 95% CI -0.81 to 0.00
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Tiredness

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Tiredness
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Tiredness-0.94 ± 0.14-1.43 ± 0.14
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0075 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.49 · 95% CI -0.89 to -0.10
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Morning

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Morning
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Morning-0.97 ± 0.15-1.56 ± 0.15
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0023 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.59 · 95% CI -1.01 to -0.18
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Stiffness

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Stiffness
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Stiffness-0.90 ± 0.15-1.05 ± 0.15
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.2568 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.14 · 95% CI -0.57 to 0.29
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Anxious

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Anxious
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Anxious-0.64 ± 0.16-0.92 ± 0.16
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.1011 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.28 · 95% CI -0.72 to 0.15
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Depression

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Depression
Scores on a scalePlaceboPregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Depression-0.51 ± 0.14-0.55 ± 0.14
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.4165 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.04 · 95% CI -0.44 to 0.35
SecondaryChange From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Physical Functioning

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Physical Functioning
Scores on a scalePlaceboPregabalin
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Physical Functioning4.72 ± 0.939.01 ± 0.93
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0006 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 4.29 · 95% CI 1.70 to 6.88
SecondaryChange From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Physical

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Physical
Scores on a scalePlaceboPregabalin
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Physical8.36 ± 1.3010.04 ± 1.30
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.1805 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 1.68 · 95% CI -1.93 to 5.29
SecondaryChange From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Bodily Pain

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Bodily Pain
Scores on a scalePlaceboPregabalin
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Bodily Pain9.50 ± 1.0611.65 ± 1.06
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0770 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 2.15 · 95% CI -0.81 to 5.10
SecondaryChange From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- General Health Perception

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- General Health Perception
Scores on a scalePlaceboPregabalin
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- General Health Perception2.83 ± 0.854.66 ± 0.85
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0648 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 1.83 · 95% CI -0.54 to 4.19
SecondaryChange From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Social Functioning

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Social Functioning
Scores on a scalePlaceboPregabalin
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Social Functioning6.84 ± 1.388.43 ± 1.37
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.2068 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 1.59 · 95% CI -2.23 to 5.41
SecondaryChange From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Emotional

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Emotional
Scores on a scalePlaceboPregabalin
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Emotional3.50 ± 1.363.27 ± 1.35
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.5480 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.23 · 95% CI -4.00 to 3.54
SecondaryChange From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Vitality

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Vitality
Scores on a scalePlaceboPregabalin
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Vitality5.12 ± 1.229.53 ± 1.21
Statistical analysis
  • Placebo · ANCOVA · p = 0.0052 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 4.42 · 95% CI 1.04 to 7.80
SecondaryChange From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Mental Health

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Mental Health
Scores on a scalePlaceboPregabalin
Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Mental Health3.33 ± 0.985.97 ± 0.98
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0287 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): 2.64 · 95% CI -0.08 to 5.37
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety

Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety
Scores on a scalePlaceboPregabalin
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety-0.09 ± 0.18-0.57 ± 0.18
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0262 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.48 · 95% CI -0.97 to 0.01
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression

Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression
Scores on a scalePlaceboPregabalin
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression0.00 ± 0.20-0.29 ± 0.20
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.1561 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -0.28 · 95% CI -0.83 to 0.27
SecondaryChange From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint

The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 15 or study discontinuation
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint
Scores on a scalePlaceboPregabalin
Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint-14.11 ± 1.45-20.30 ± 1.44
Statistical analysis
  • Placebo vs Pregabalin · ANCOVA · p = 0.0013 (The analysis was conducted using 1-sided test with the significance level of 0.025.) · Mean difference (final values): -6.19 · 95% CI -10.20 to -2.18

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/248 (0%)113/248 (45.6%)
Pregabalin—1/250 (0.4%)195/250 (78%)
Most frequent serious events
Most frequent serious events
EventPlaceboPregabalin
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2481/250
Most frequent other events
Most frequent other events
EventPlaceboPregabalin
SomnolenceNervous system disorders45/248116/250
DizzinessNervous system disorders15/24874/250
NasopharyngitisInfections and infestations45/24845/250
Weight increasedInvestigations9/24839/250
ConstipationGastrointestinal disorders17/24836/250
Feeling abnormalGeneral disorders3/24820/250
Oedema peripheralGeneral disorders3/24818/250
HeadacheNervous system disorders15/24815/250
Vision blurredEye disorders3/24813/250

Baseline characteristics

Age, Customized
Age, Customized(Participants)PlaceboPregabalinTotal
<18 years000
Between 18 years and 44 years104101205
Between 45 years and 64 years123125248
>=65 years212445
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPregabalinTotal
Female217226443
Male312455
08

Study locations

37 sites
  • Pfizer Investigational Site
    Nagoya, Aichi, Japan
  • Pfizer Investigational Site
    Ichihara-shi, Chiba, Japan
  • Pfizer Investigational Site
    Yotukaidou, Chiba, Japan
  • Pfizer Investigational Site
    Matuyama-si, Ehime, Japan
  • Pfizer Investigational Site
    Fukuoka-shi, Fukuoka-ken, Japan
  • Pfizer Investigational Site
    Iiduka, Fukuoka, Japan
  • Pfizer Investigational Site
    Kitakyusyu, Fukuoka, Japan
  • Pfizer Investigational Site
    Takasaki, Gunma, Japan
  • Pfizer Investigational Site
    Sapporo-shi, Hokkaido, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site
    Kobe, Hyogo, Japan
  • Pfizer Investigational Site
    Kobe, Hyougo, Japan
  • Pfizer Investigational Site
    Mito, Ibaraki, Japan
  • Pfizer Investigational Site
    Morioka, Iwate, Japan
  • Pfizer Investigational Site
    Sagamihara-shi, Kanagawa, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Koushi, Kumamoto, Japan
  • Pfizer Investigational Site
    Tsu, Mie, Japan
  • Pfizer Investigational Site
    Sendai, Miyagi, Japan
  • Pfizer Investigational Site
    Hiki-gun, Saitama, Japan
  • Pfizer Investigational Site
    Saitama-city, Saitama, Japan
  • Pfizer Investigational Site
    Saitama-shi, Saitama, Japan
  • Pfizer Investigational Site
    Aoi-ku, Shizuoka, Japan
  • Pfizer Investigational Site
    Shimotsuga-gun, Tochigi, Japan
  • Pfizer Investigational Site
    Bunkyo-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Chiyoda-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Chuou-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Itabashi-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya, Tokyo, Japan
  • Pfizer Investigational Site
    Shinagawa-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Toyama-shi, Toyama, Japan
  • Pfizer Investigational Site
    Nagano, Japan
  • Pfizer Investigational Site
    Oita, Japan
  • Pfizer Investigational Site
    Osaka, Japan
  • Pfizer Investigational Site
    Tokushima, Japan
  • Pfizer Investigational Site
    Yokohama, Japan
09

References and documents

Publications

  • Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601-9. doi: 10.1185/03007995.2015.1134463. Epub 2016 Jan 27. PubMed 26694975 ↗
  • Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012 Oct 12;14(5):R217. doi: 10.1186/ar4056. PubMed 23062189 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2009
First posted
Jan 27, 2009
Start
Mar 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Jun 1, 2012
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00830167
Responsible party
Sponsor
First posted
Jan 27, 2009
Start date
Mar 2009
Primary completion
May 2011
Completion
May 2011
Results posted
Jun 1, 2012
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion